**Claims**

1. A compound comprising a first peptide linked to a second peptide by a linker, wherein the first and the second peptide comprise at least four amide-bonded residues having a sequence YTXV or YSXV, wherein
    a. Y is selected from among E, Q, and A, and
    b. X is selected from among A, Q, D, N, *N*-Me-A, *N*-Me-Q, *N*-Me-D, and *N*-Me-N, and

    wherein the linker comprises PEG and, wherein at least one oxygen atom of the PEG is substituted with a nitrogen atom to give *N*PEG,
    wherein a Cell Penetrating Peptide (CPP) is linked to the nitrogen atom of the linker by an amide bond, and
    wherein the CPP comprises at least 4 amino acid residues selected from arginine and/or lysine.

2. TheA compound according to claim 1, wherein the linker comprises 4 to 28 ethylene glycol moieties (N=4-28).

3. TheA compound according to claim 1 or 2, wherein the linker is an *N*PEG-diacid linker, and wherein each carboxyl group of the linker is linked to a terminal residue of the first or the second peptide or peptide analogue.

4. TheA compound according to any one of claims 1-3, wherein the CPP comprises a retroinverso peptide.

5. TheA compound according to any one of claims 1-4, wherein the CPP is a Tat peptide having amino acid sequence YGRKKRRQRRR or a Retroinverso-d-Tat peptide having amino acid sequence of rrrqrrkkr .


6. TheA compound according to any one of claims 1-5, wherein the first peptide and/or the second peptide is from 5 to 10 amide-bonded residues in length.

7. The~~A~~ compound according to any one of claims 1-6, wherein the first and/or second peptide is comprised of at least 4 L-amino acid residues.


8. The~~A~~ compound according to any of claims 1-7, wherein X is selected from ~~among~~ the group consisting of A, Q, and D.

9. The~~A~~ compound according to any one of claims 1-8, wherein the first peptide and/or the second peptide is *N*-alkylated.


~~9.~~10. The compound according to claim 1, wherein said compound is selected from the group consisting of:





a) **AB144**




b) **AB147**




c) **AB144_B** , and




d) **AB144_C** .

~~10.~~11. A ~~pharmaceutical composition comprising a~~ compound according to any one of claims 1-~~9~~ 10 for use as a medicament.

~~11.~~12. ~~A pharmaceutical composition for use~~ Use of a compound according to any one of claims 1-10 ~~in~~ for the preparation of a medicament for the prophylaxis and/or treatment of an excitotoxic-related disease in a subject.

~~12.~~13. The~~A~~ ~~pharmaceutical composition for~~ use according to claim ~~11~~12, wherein the disease is ischemic or traumatic injury of the CNS.

~~13.~~14. Use of a compound according to any one of claims 1-10 for the preparation of a medicament for~~A pharmaceutical composition for use according to claim 10~~ ~~in~~ the prophylaxis and/or treatment of pain in a subject.

~~14.~~15. A kit comprising the compound ~~pharmaceutical composition~~ according to any one of claims ~~14~~ to ~~13~~10, further comprising means for delivering said composition to a subject.

~~15.~~16. Use of a ~~A pharmaceutical composition for use in the prophylaxis and/or treatment of pain in a subject comprising a compound, said~~ compound comprising ~~a~~ first peptide linked to a second peptide by a linker, wherein the first and the second peptide comprise at least four amide-bonded residues having a sequence YTXV or YSXV, wherein

a. Y is selected from among E, Q, and A, ~~,~~ and

b. X is selected from among A, Q, D, N, *N*-Me-A, *N*-Me-Q, *N*-Me-D, and *N*-Me-N;

for the preparation of a medicament for the prophylaxis and/or treatment of pain.

~~16.~~17. The~~A~~ use ~~pharmaceutical composition~~ according to claim ~~15~~16, wherein the linker is a PEG linker and comprises 4 to 28 ethylene glycol moieties (N=4-28).

~~17.~~18. The~~A~~ use ~~pharmaceutical composition~~ according to claim ~~16~~17, wherein the linker is a PEG-diacid linker and each carboxyl group of the linker is linked to a terminal residue of the first or the second peptide.

~~18.~~19.The~~A~~ use ~~pharmaceutical composition~~ according to claim ~~16~~17, wherein said compound is selected from the group consisting of ~~among~~ PEG4(IETAV)$_2$, *N*PEG4(IETAV)$_2$, PEG6(IESDV)$_2$, and PEG4(IESDV)$_2$.